Olivier Bylicki
Toulon, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 79 publications
Trauma critical care in trauma patients during large-scale combat operations: gaps but also concrete advances.
Journal: The journal of trauma and acute care surgery
Published: July 15, 2026
Participant-Reported Preference for Pembrolizumab Administered Subcutaneously or Intravenously: A Randomized, Open-Label, Phase II Study.
Journal: JCO oncology practice
Published: June 03, 2026
Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 21, 2026
Organized Lung Cancer Screening of Subjects Occupationally Exposed to Lung Carcinogens: The LUng Cancer Screening Occupational exposure Study Entry Findings.
Journal: JTO clinical and research reports
Published: November 10, 2025
Response to the Letter of Mehmet Mutlu Çatlı, Arif Hakan Önder.
Journal: Clinical lung cancer
Published: October 15, 2025
Survival of Patients with Lung Adenocarcinoma Diagnosed in 2000, 2010, and 2020.
Journal: NEJM evidence
Published: June 24, 2025
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial.
Journal: The Lancet. Respiratory medicine
Published: May 06, 2025
Alectinib Efficacy Post-Brigatinib Against Advanced ALK+ Non-Small Cell Lung Cancer (BrigALK2-GFPC 02-2019 Study).
Journal: Lung Cancer (Auckland, N.Z.)
Published: April 22, 2025
Rebiopsy Feasibility and Clinical Impact on Metastatic Non-Small-Cell Lung Cancer With EGFR/ALK/ROS Oncogenic Driver Progression After Optimal Targeted Therapy: A Multicenter Real-World Analysis.
Journal: Clinical lung cancer
Published: April 21, 2025
Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.
Journal: Nature medicine
Published: April 01, 2025
Osimertinib - maintenance therapy after radiochemotherapy for locally advanced non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858R mutation
Journal: Bulletin du cancer
Published: February 19, 2025
Last Updated: 09/26/2026